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Background: There is increasing global awareness and interest in the use of cannabis for therapeutic purposes
(CTP). It is clear that health care professionals need to be involved in these decisions, but often lack the education
needed to engage in informed discussions with patients. This study was conducted to determine the educational
needs of Canadian physicians regarding CTP.
Methods: A national needs assessment survey was developed based on previous survey tools. The survey was
approved by the Research Ethics Board of the McGill University Health Centre Research Institute and was provided
online using LimeSurvey®. Several national physician organizations and medical education organizations informed
their members of the survey. The target audience was Canadian physicians. We sought to identify and rank using
5-point Likert scales the most common factors involved in decision making about using CTP in the following
categories: knowledge, experience, attitudes, and barriers. Preferred educational approaches and physician
demographics were collected. Gap analysis was conducted to determine the magnitude and importance of
differences between perceived and desired knowledge on all decision factors.
Results: Four hundred and twenty six responses were received, and physician responses were distributed across
Canada consistent with national physician distribution. The most desired knowledge concerned “potential risks of
using CTP” and “safety, warning signs and precautions for patients using CTP”. The largest gap between perceived
current and desired knowledge levels was “dosing” and “the development of treatment plans”.
Conclusions: We have identified several key educational needs among Canadian physicians regarding CTP. These
data can be used to develop resources and educational programs to support clinicians in this area, as well as to
guide further research to inform these gaps.
Keywords: Cannabis, Medical marijuana, Needs assessment, Continuing medical education, Health professionalsBackground
Canadian patients have had access to cannabis for thera-
peutic purposes (CTP) under Health Canada’s Medical
Marihuana Access Program (MMAP) since 1999. As of
June 2013, over 30 000 Canadians had licenses to pos-
sess CTP; this was projected to reach approximately 50
000 in 2014 and 400 000 in 2024 [1]. The new Marihuana
for Medical Purposes Regulations (MMPR), which came
into effect on 19 June 2013, completely replaced the
Medical Marihuana Access Regulations (MMAR) on April* Correspondence: mark.ware@mcgill.ca
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unless otherwise stated.1 2014 [2]. Under the MMPR, patients may be authorised
to possess herbal cannabis if they are issued a valid med-
ical document from either a physician or a nurse practi-
tioner; the medical document is not strictly speaking a
‘prescription’ as cannabis is not an approved drug, but it
does contain information on daily ‘dose’ of cannabis (in
grams/day) and duration of validity. No diagnosis is re-
quired as there is no formal ‘indication’ for CTP. The
MMPR therefore maintains the physician’s pivotal role in
patients’ access to CTP, despite concerns expressed by
physicians about insufficient information on the risks and
benefits of CTP, insufficient information regarding the ap-
propriate use of CTP [3,4] and insufficient information with
which to compare CTP with pharmaceutical cannabinoids.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cannabis legalization [5-8] and attitudes towards CTP
[9,10]. CTP-related surveys have been directed at spe-
cific physician populations, including oncologists [6-8]
or family physicians [9]. The need for further medical
education and training on CTP has been reported by
Colorado family physicians [9] and American oncologists
[6]. An understanding of the current and desired status
of Canadian physicians’ educational needs on CTP re-
mains to be quantified. We therefore conducted an edu-
cational needs assessment among Canadian physicians
to quantify perceived knowledge levels and identify
knowledge and practice gaps. This survey was also de-
signed to explore Canadian physicians’ experiences and
attitudes towards CTP, to list perceived barriers to the
use of cannabis as a possible treatment option in clinical
practice, and to make recommendations for the pre-
ferred format of physician education on CTP. The study
was conducted in order to inform strategies to overcome
knowledge and practice gaps, to increase competence
and to improve patient care in this complex and contro-
versial area.
Methods
We conducted an online survey of Canadian physicians
from November 2012 to March 2013. Physicians were
contacted through existing medical and health care orga-
nizations, which were asked to distribute the survey to
their members. Direct email invitations to physician
members were sent by five organizations, and links from
organization websites to the survey were provided by
three organizations. Electronic invitations included a
summary of the survey, consent information and a link
to access the online survey.
Survey questions were adapted from prior needs assess-
ment surveys distributed by the Canadian Consortium for
the Investigation of Cannabinoids (CCIC) between 2009
and 2012 [4]. The research team reviewed the survey for
construct validity and four physicians (a rheumatologist,
anesthesiologist, internist, and pain specialist) pilot-
tested the survey. Limesurvey® (https://www.limesurvey.
org/en/) was selected to host the survey as it is sup-
ported by McGill University and data are securely
stored within the institution. The study protocol was
approved by the McGill University Health Centre
Research Institute Research Ethics Board.
The survey consisted of six sections. The first section
concerned knowledge factors – respondents were asked
to rank their perceived current and desired level of
knowledge on 9 CTP-related topics (see Table 1) using a
5-point Likert scale (1: very poor; 5: very good). They
were also asked to rank how strongly they felt the need
for education on CTP using a 5-point Likert scale (1: not
at all; 5 very strongly). The second section addressedexperience – five questions with binary responses (yes or
no) explored physicians’ clinical experiences with pharma-
ceutical cannabinoids, the federal MMAR process and dis-
cussions regarding CTP with their patients. The third
section addressed barriers – a list of potential barriers
regarding the use of CTP were offered, from which the
respondents could select one or more, as well as the op-
portunity to indicate any other obstacles to the use of
CTP in their practice. The fourth section concerned at-
titudes – respondents were asked to specify which
health care professionals, if any, they felt should be au-
thorized to approve CTP for patient use. They were also
asked to rank, using a 5-point Likert scale (1: strongly
agree; 5: strongly disagree), how strongly they agreed
with a series of statements about personal comfort
levels with prescribing or authorizing CTP. The fifth
section addressed educational approaches - eleven com-
monly used educational methods were listed from which
respondents were asked to select their preferences, along
with an opportunity to provide other alternatives or com-
ments. Finally, the sixth section requested demographic
information - respondents were asked to indicate region,
setting and focus of their practice, and number of years in
practice. The survey took an estimated 10–15 minutes
to complete.
Data analysis
Descriptive statistics (frequencies and percentages) were
used to summarize respondents’ knowledge, experi-
ences, barriers, attitudes, preferred educational ap-
proaches, and demographic information. Open-ended
comments were reviewed for common themes, sorted
and counted. Data were entered and analysed using
Microsoft Excel® (Redmond, USA).
The difference between current and desired knowledge
levels was used to determine a perceived knowledge gap.
The knowledge gap was calculated based on how much
greater the individual, not average, desired knowledge
level was compared to their current knowledge level.
Only response pairs were used for the calculation; re-
sponses only to the current or desired question were ex-
cluded, and responses where the indicated desired level
was lower than the current level were also excluded.
Results
Participant demographics
Eight of 15 organizations contacted agreed to distribute
the survey to their members or to post the survey on their
websites. Participating organizations were the Canadian
Association for HIV Research, the Canadian HIV Trials
Network, the University of British Columbia Faculty of
Medicine Office of Continuing Medical Education, the
Canadian Association for Physical Medicine and Rehabili-
tation, the Canadian Consortium for the Investigation of
Table 1 Analysis of knowledge scores and gaps for therapeutic use of cannabis (ranked by gap size)





Dosing and creating effective treatment plans for patients using
medical cannabis
2.25 3.95 1.78
Similarities and differences between dried cannabis, other forms
of cannabis products, and prescription cannabinoid medications
2.36 4.00 1.70
Health Canada’s Marihuana Medical Access Regulations (MMAR) Program 2.43 3.99 1.60
Laws and regulations surrounding the medical use of cannabis 2.65 4.11 1.49
Safety, warning signs and precautions for patients using medical cannabis 2.84 4.21 1.48
Alternative routes of administration of medical cannabis 2.72 4.02 1.42
Mechanism of action of cannabis (endocannabinoid system) 2.78 4.06 1.39
Potential risks of using cannabis for medical purposes 3.06 4.23 1.28
Potential therapeutic uses for cannabis 3.07 4.17 1.22
1Gap is calculated (using individual response pairs) = (desired knowledge level -current knowledge level).
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Professional Development Office, MedCanAccess, and
RxMedia Healthcare Communications Inc. Based on
the estimated size of organisational mailing lists and
organisation member outreach, we estimated that a
total of 25,298 invitations to participate were sent. The
survey was accessed a total of 580 times. From the total
number of times accessed, 108 did not proceed past
the introduction and consent page, 19 viewed the survey
but did not provide any responses, and 27 did not submit
their responses. A total of 426 usable and complete re-
sponses were received.
Demographic characteristics of respondents are pre-
sented in Table 2. Just over half of the respondents
(54%) were physicians with 21 years or more in practice.
While we do not have national data on the distribution
of physicians by years of practice, 42% of physicians are
over the age of 55y in Canada, and 68.1% are over 45y,
suggesting that our sample is roughly consistent with
national physician demographics [11]. The survey was
completed in English by 91% and in French by 9% of re-
spondents. Respondents’ region and setting of practice
were roughly proportional to the Canadian national
physician distribution [12].
Knowledge
The perceived current and desired knowledge levels on
9 CTP related sub-topics are shown in Table 1. The low-
est average current knowledge levels were found for dos-
ing and creating effective treatment plans for patients
using CTP (2.25/5) and similarities and differences be-
tween dried cannabis, other forms of cannabis products,
and prescription cannabinoid medications (2.36/5). The
highest average desired knowledge levels concerned po-
tential risks of using CTP (4.23/5) and safety, warning
signs and precautions for patients using CTP (4.21/5);
for these topics, 87.5% and 87.3% of respondents desireda good or very good level of knowledge respectively. The
largest gap between perceived current and desired know-
ledge levels was identified for dosing and the develop-
ment of treatment plans (average gap = 1.78) followed by
comparison of cannabis, cannabis products and prescrip-
tion cannabinoids (average gap = 1.70) and knowledge of
the regulatory framework (average gap = 1.60). The need
for education on cannabis in medicine was reported as
strong or very strong by 64% of respondents, compared
to 19% who were neutral, and 17% not very strongly or
not at all.Experiences
Most respondents (79%) reported having been
approached by a patient and/or his/her family to discuss
the use of CTP, while 39% reported initiating a discus-
sion with a patient and/or his/her family on the use of
CTP. Two-thirds of respondents (66%) reported having
patients using CTP, while 36% reported having ever
signed a medical declaration for the MMAR. Experi-
ences with pharmaceutical cannabinoid medications
were varied. Of the 59% who had ever prescribed a canna-
binoid, nabilone was the most common (51%), followed by
dronabinol (19%) and nabiximols (18%), while 41% of re-
spondents reported having never prescribed a pharma-
ceutical cannabinoid.Barriers
The list of barriers to the use of CTP are shown in
Table 3. The most common was a concern that patients
who request CTP may actually want it for recreational
purposes (65%), while a lack of guidelines for the clinical
use of cannabis and the need for more data on risks and
benefits were reported by 64% and 56% of respondents,
respectively.
Table 2 Demographic characteristics of needs assessment




GP/FP with enhanced area 72 17
Specialist 219 51
Other1: 6 1
Not specified 12 3
Number of years in practice
0 to 5 40 9
6 to 10 39 9
11 to 15 45 11
16 to 20 59 14
21 or more 230 54













Not specified 12 3
Language of survey completion
English 388 91
French 38 9
1Resident (2), Medical Advisor (2), Not Specified (2).
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When asked which health care professionals should be
authorized to approve CTP, 85% reported that specialist
physicians and 74% reported that family physicians
should have this authority. Respondents were divided re-
garding nurse practitioners; 25% of respondents believed
that they should and 60% believed they should not be
authorized to approve CTP. The majority of respondents
believed that other health care professionals should not
be authorized to approve CTP (Table 4).
Seventy-one percent of respondents reported that they
would feel more comfortable discussing CTP with pa-
tients/patient family members if they had more education
about it, and 70% felt that with more education they
would be better able to treat patients using cannabis.Comfort level with CTP was also influenced by liability
protection (62%) or the availability of specific training for
physicians to participate in the program (61%) (Table 5).
Educational approaches
The preferred formats for receiving educational informa-
tion were peer-reviewed literature reviews on specific
topics (55%), online learning programs as part of continu-
ing medical education (54%), online resources (46%),
workshops/small-group learning sessions (45%) and sym-
posia/conferences (44%) (Table 6).
Discussion
There is a clear need for education for health care profes-
sionals on the use of CTP. We report the results of a na-
tional survey of Canadian physicians’ perceived knowledge
gaps and perceived needs concerning CTP. We found that
the largest gaps between current and desired knowledge
concerned dosing, the development of treatment plans, and
comparisons between cannabis and existing prescription
cannabinoids. There was an expressed need for better
knowledge of the risks and benefits of CTP. Respondents
thought that both specialists and family physicians were
capable of authorising CTP; however, overall it was felt that
pharmacists or naturopathic doctors should not have this
authority. Concerns regarding the recreational use of can-
nabis masquerading as medical use was common among
respondents. Respondents reported that their comfort level
in including CTP in their practice would increase with add-
itional education, and reported their educational needs
would be best met with focused literature reviews, online,
and small group continuing medical education activities.
Ranking perceived knowledge levels on several related
topics allows a comparison of ‘what is’ and ‘what should
be’ regarding perceived educational needs, and enables the
quantification of perceived knowledge gaps. Describing
and ranking the perceived knowledge gaps for several
CTP subtopics enables a comparison of gaps between
topics, and enables the identification of strategies to re-
duce the gaps [13,14]. Based on our data, Canadian physi-
cians perceive their current knowledge level on CTP to be
low, while desiring a high knowledge level, consistent with
other reports that physicians desire education on CTP
[9,10]. More specifically, we identified the lowest perceived
knowledge levels, and largest knowledge gaps, to be re-
garding hands-on clinically relevant CTP subtopics, in-
cluding; dosing and treatment plans, comparing between
cannabinoids, and Canadian CTP regulations. In contrast,
we identified higher perceived current knowledge levels,
and smaller knowledge gaps, to be regarding more theory-
based CTP subtopics, including; the mechanism of action
of cannabis, potential risks, and potential benefits. This
suggests that practical hands-on style information should
be prioritized.
Table 3 Perceived barriers regarding the use of CTP
Factor n1 %
Concern that patients who request medical cannabis may actually want it for recreational purposes 279 65
Lack of clinical guidelines for the use of cannabis for medical purposes 271 64
Risks and benefits are not sufficiently clear for potential therapeutic uses 237 56
Lack of personal knowledge/education or information regarding the use of cannabis for medical purposes 214 50
Insufficient information regarding the appropriate use of cannabis for medical purposes 212 50
Instruction from medical associations, licensing bodies, Royal College, College of Family Physicians or Canadian
Medical Protective Association
201 47
Potential liability concerns 194 46
Concern about possible side effects 190 45
Uncertainty about possible interactions with other medications 167 39
Belief that cannabis is not an appropriate treatment in a specific case 141 33
Requirement to sign a declaration indicating awareness that cannabis is not an approved therapeutic under the
Food and Drug Regulations
138 32
Uncertainty over whether cannabis has any medicinal value 117 27
Availability of prescription cannabinoids (e.g. nabiximols, dronabinol or nabilone) 98 23
Other 66 15
1Subjects may choose more than one response.
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about experiences with the clinical use of CTP. Firstly,
patients initiate most of the discussions about CTP, and
physicians feel they have insufficient information and
lack guidance on the topic. Few guidelines exist for CTP
[15,16], while Canadian physicians have reported that
clinical practice guidelines would be useful or very useful
[3]. Secondly, only one third of respondents had signed
a patient’s application to possess CTP through the feder-
ally regulated program, yet two thirds reported having
patients using CTP. It is possible that respondents had
patients who had received CTP from another physician.
The discrepancy between the prevalence of self reported
use of CTP (48%) and the proportion of patients withTable 4 Beliefs about which health care professionals
should have authority to approve/prescribe CTP
Health care professional Yes No
N %1 N %
Specialist physicians 363 85 42 10
Primary care physicians/family physicians 316 74 94 22
Nurse practitioners 108 25 256 60
Pharmacists 67 16 285 67
Naturopathic doctors 60 14 293 69
Traditional Chinese medicine practitioners 49 12 303 71
Nurses 28 7 321 75
1Percentages may not add up to 100% as missing data or non-responses are
not included.legal access through Canada’s federal program (32%) has
been reported previously in certain populations [17,18].
The highest reported obstacle to CTP was found to be a
concern that patients are actually seeking cannabis for rec-
reational purposes, supporting similar results from previ-
ous reports [4,9,10]. Patients report experiencing a lack of
trust by health care providers, and suggest that it is due to
the stigma associated with cannabis as an illegal recre-
ational drug [17]. Such views may be a result of the
blurred lines between therapeutic and recreational use re-
ported in the media [19]. Another potential cause for this
distrust of patient motivation for CTP use stems from the
fact that some of the patient populations in which cannabis
may be a potential therapeutic option, such as chronic pain,
HIV/AIDS, and mental health issues, are already stigma-
tized [17]. Canadian patients using CTP have reported the
stigma associated with cannabis negatively impacts their re-
lationship with health care providers, creating a barrier to
receiving the health care they need, and increased levels of
physician education may be a means to decrease the stigma
[17]. It may be the case that negative attitudes and values
about cannabis in general influence potential therapeutic
uses, as has been reported in other controversial thera-
peutic areas like methadone maintenance therapy [20]. Fi-
nally, the demographic overlap (young white males)
between medical cannabis users and recreational users also
adds to the potential for physician mistrust of the real med-
ical ‘necessity’ for CTP [21,22].
Our survey has several potential limitations. The low
number of responses creates a potential selection bias,
which affects our ability to generalize findings, and
Table 5 Factors influencing comfort level of the clinical use of cannabis for therapeutic purposes
Factor Agree* Neutral Disagree*
N % N % N %
I would feel more comfortable discussing the medical use of cannabis with patients/patient family members if
I had more education about it
304 71 56 13 54 13
I feel that with more education I would be better able to treat patients using medical cannabis 300 70 57 13 56 13
I would feel more comfortable authorizing medical cannabis if Health Canada offered me protection from liability 265 62 87 20 60 14
I would feel more comfortable if physicians who participated in access to CTP were required to undergo a specific
training or licensing program
259 61 81 19 74 17
Percentages may not add up to 100% as missing data or non-responses are not included.
*Likert scale responses were collapsed to dichotomous outcomes: agree (strongly agree and agree) and disagree (strongly disagree and disagree).
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overall. A true response rate is impossible to calculate, as
the denominator is unknown; we do not know how many
different physicians received or saw the survey. The low
number of overall responses may be due, in part, to the
lack of monetary compensation for participation [23], a
large number of similar requests, lack of time, or hesitancy
to enter answers into a survey on this topic. Another con-
tributing factor to the low number of responses may be the
source of the invitations; other non-medical-college distrib-
uted surveys have reported similarly low response rates
from Canadian physicians [24], whereas surveys sent by
provincial or national medical colleges or associations have
reported response rates around 20% or higher [9,10,20,25].
An additional limitation is that a number of recipients of
email invitations were based on lists of previous partici-
pants in CTP-related continuing medical education pro-
grams, or those who had expressed interest in topic of
CTP to a variety of sources. This may have selected partici-
pants with specific interest in CTP or who had already had
some education on this topic. However the number of re-
sponses received is similar to other recent physician sur-
veys on CTP including the 607 responses received by theTable 6 Preferred formats of educational information
Format n1 %
Peer-reviewed literature reviews on specific topics 236 55
On-line learning programs as part of continuing
medical education
230 54
On-line resources 195 46
Workshops/small-group learning sessions 192 45
Symposia/conferences 188 44
A monograph on cannabis (similar to a drug product monograph 169 40
Expert speaker tour 149 35
Grand rounds 141 33
Topic-specific reports 97 23
Mentorship/preceptorship program 79 19
Newsletter 63 15
Other 39 9
1Subjects may choose more than one response.Canadian Medical Association (CMA) [10], and 520 re-
sponses to the Colorado physician survey [9]. Finally, this
study is limited by the focus on perceived needs and did
not include an assessment of unperceived needs; we did
not determine whether high levels of perceived knowledge
were in fact truly high levels of knowledge based on exter-
nal evaluation. Triangulating perceived needs with unper-
ceived needs should be the focus of further research.
Our results support the need for further medical educa-
tion and training on CTP [9]. In alignment with expressed
needs for more information on CTP, physicians reported
that focused peer-reviewed summaries on specific CTP
sub-topics would be helpful in enhancing their knowledge
on this area. The preference for online education is consist-
ent with trends towards e-learning in the health professions
[26]. Additionally, studies have reported that educational
interventions that enhance competencies and skills have a
direct influence on improvement of patient outcomes [27].
Conclusions
Cannabis is not a pharmaceutical product and thus has not
taken a traditional route into the physicians’ toolbox of po-
tential therapies and has not undergone the same rigorous
testing demanded by Health Canada of pharmaceutical
medications. However, research on cannabinoids and the
endocannabinoid system has increased over the past
20 years. This growing body of research needs to be trans-
lated into resources to address physicians’ professional
knowledge and practice gaps to enable them to make more
informed decisions about CTP. The new MMPR allows
nurse practitioners and physicians to authorize patients’
legal access to CTP. The knowledge gaps and educational
needs among nurse practitioners is yet to be described. Fu-
ture needs assessments among physicians and nurse practi-
tioners should evaluate unperceived needs in addition to
perceived needs. The transition to the new federal regula-
tions provides an opportunity to develop and implement
evidence-based education for physicians and nurse practi-
tioners that should address the existing perceived know-
ledge gaps we describe, and to evaluate the effectiveness of
such strategies on clinical practice and, ultimately, on
health outcomes.
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